Ocugen Cash Balance Jumps 5.4x on Convertible Notes Deal
Ocugen closed a $130.0 million convertible notes offering that pushed its cash position to $100.4 million and cleared the way for a Phase 3 trial in geographic atrophy.
Ocugen (OCGN) ended the second quarter with $100.4 million in cash, cash equivalents, and restricted cash, up from $32.2 million at March 31 and roughly 5.4 times the $18.6 million to $18.9 million it held at the end of 2023. The increase came from the close of a $130.0 million convertible notes offering, which generated $112.5 million in net proceeds and replaced a higher-cost debt load with equity-linked financing.
The clinical-stage biotechnology company used roughly $32.7 million of the note proceeds to fully retire its Avenue Capital loan, which had carried a 12.25% interest rate. Total debt fell to $1.7 million as of June 30 from $28.8 million at year-end 2023. In its place, Ocugen added a $116.1 million convertible note liability to its balance sheet, a trade that lowered near-term interest costs but introduced new mark-to-market exposure tied to the notes' embedded derivative.
That exposure showed up in the quarter's results. Net loss widened to $24.9 million from $14.7 million a year earlier, a 69% increase, while net loss per share rose to $0.07 from $0.05. Total operating expenses climbed 18% to $17.9 million from $15.2 million, with research and development spending up 27% to $10.7 million and general and administrative costs up 6% to $7.2 million. The larger driver of the loss, however, sat below the operating line: interest expense rose to $4.5 million from $1.3 million, and the company recorded a new $2.4 million loss on debt extinguishment tied to the Avenue payoff plus a $1.9 million change in the fair value of the convertible notes' derivative liability. Shares outstanding grew to 339.0 million from 312.4 million at year-end, an 8.5% increase reflecting dilution from the financing. Stockholders' equity moved to a deficit of $(16.6) million from $(12.2) million as the accumulated deficit grew to $452.1 million from $408.1 million.
The cash raised extends its runway into 2028, a target it had flagged as pending through the first quarter and the mid-quarter notes update and now describes as backed by closed financing.
The balance-sheet work coincided with regulatory progress on OCU410, Ocugen's gene therapy candidate for geographic atrophy. The Food and Drug Administration cleared the company to begin the Phase 3 ArMaDa3 trial and granted the program Regenerative Medicine Advanced Therapy designation, both disclosed for the first time in the anchor release after a quarter of design-alignment discussions with the FDA and European Medicines Agency. The trial itself will be smaller than previously outlined: Ocugen revised the enrollment target to approximately 237 subjects, down from the "up to 300 subjects" figure cited in the fourth-quarter and first-quarter releases.
OCU400, the company's candidate for retinitis pigmentosa, completed Process Performance Qualification batches supporting a future Biologics License Application and commercial launch supplies, moving past prior-quarter language describing the work as merely on track. The regulatory pathway for that program shifted in tone: where the first-quarter release had guided to a rolling BLA submission starting in the third quarter of 2026 with completion by the second quarter of 2027, the anchor release ties the filing to topline data expected in the first quarter of 2027, with submission to follow.
Ocugen also disclosed a binding term sheet with Roots Pharmaceutical and Al-Dhow International granting an exclusive OCU400 license for the Middle East and North Africa region, carrying up to $255 million in potential sales milestones and a 22% royalty on net sales. The company named Mohamed Genead, M.D. as chief medical officer effective June 11 and Chris Clark as head of corporate communications effective July 16, rounding out a quarter that paired the financing with expanded clinical and commercial infrastructure.